EASL 2014

Edward Gane of Auckland Clinical Studies, New Zealand, presenting at EASL 2014; photo by Liz Highleyman, hivandhepatitis.com Edward Gane of Auckland Clinical Studies, New Zealand, presenting at EASL 2014; photo by Liz Highleyman, hivandhepatitis.com

Sofosbuvir/ledipasvir

Co-formulation is safe and effective for relapsers and hard-to-treat patients

Guidelines panel at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.Guidelines panel at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.

New EASL guidelines

European liver specialists recommend use of newest hepatitis C drugs

Professor Stefan Zeuzem speaking at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.Professor Stefan Zeuzem speaking at the International Liver Congress 2014. Photo by Liz Highleyman, hivandhepatitis.com.

Interferon-free regimen

AbbVie regimen cures 96% of treatment-experienced people with HCV genotype 1

infohep news